ORTX Key Statistics, Chart & Performance
The current stock price of ORTX is 16.7 USD. In the past month the price increased by 1.58%. In the past year, price increased by 195%.
ORTX Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to ORTX. When comparing the yearly performance of all stocks, ORTX is one of the better performing stocks in the market, outperforming 98.06% of all stocks.
ORTX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ORTX. ORTX may be in some trouble as it scores bad on both profitability and health.
ORTX Financial Highlights
Over the last trailing twelve months ORTX reported a non-GAAP Earnings per Share(EPS) of -4. The EPS increased by 71.01% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -36.05% | ||
| ROE | -90.81% | ||
| Debt/Equity | 0.2 |
ORTX Forecast & Estimates
7 analysts have analysed ORTX and the average price target is 16.32 USD. This implies a price decrease of -2.28% is expected in the next year compared to the current price of 16.7.
For the next year, analysts expect an EPS growth of 74.37% and a revenue growth 24% for ORTX
ORTX Ownership
ORTX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.01 | 384.23B | ||
| AMGN | AMGEN INC | 15.18 | 178.72B | ||
| GILD | GILEAD SCIENCES INC | 14.99 | 152.31B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.5 | 112.31B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.77 | 79.33B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 712.34 | 47.99B | ||
| INSM | INSMED INC | N/A | 34.60B | ||
| NTRA | NATERA INC | N/A | 33.09B | ||
| BIIB | BIOGEN INC | 10.09 | 24.79B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 23.78B | ||
| INCY | INCYTE CORP | 16.34 | 20.60B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.93 | 20.38B |
Related stock screener links
About ORTX
Company Profile
Orchard Therapeutics Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing and commercializing gene therapies for patients with rare disorders. The firm is engaged in transforming the lives of people affected by rare diseases through the development of curative gene therapies. Its ex vivo autologous hematopoietic stem cell (HSC), gene therapy approach harnesses the power of genetically modified blood stem cells and seeks to correct the underlying cause of disease in a single administration. Its ex vivo autologous HSC gene therapy approach seeks to transform a patient’s autologous HSCs into a gene-modified cellular drug product to treat the patient’s disease. Its lead program is OTL-200 operates under the brand name Libmeldy for eligible patients with early-onset metachromatic leukodystrophy (MLD). Its programs in immunological disorders consist of two pre-clinical programs, OTL-104 for Crohn’s disease with mutations in the nucleotide-binding oligomerization domain-containing protein 2 (NOD2-CD), and OTL-105 for hereditary angioedema (HAE).
Company Info
ORCHARD THERAPEUTICS PLC-ADR
245 Hammersmith Road, 3Rd Floor
London EC4N 6EU GB
CEO: Bobby Gaspar
Employees: 166
Phone: 114402033846700
ORCHARD THERAPEUTICS PLC-ADR / ORTX FAQ
Can you describe the business of ORCHARD THERAPEUTICS PLC-ADR?
Orchard Therapeutics Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing and commercializing gene therapies for patients with rare disorders. The firm is engaged in transforming the lives of people affected by rare diseases through the development of curative gene therapies. Its ex vivo autologous hematopoietic stem cell (HSC), gene therapy approach harnesses the power of genetically modified blood stem cells and seeks to correct the underlying cause of disease in a single administration. Its ex vivo autologous HSC gene therapy approach seeks to transform a patient’s autologous HSCs into a gene-modified cellular drug product to treat the patient’s disease. Its lead program is OTL-200 operates under the brand name Libmeldy for eligible patients with early-onset metachromatic leukodystrophy (MLD). Its programs in immunological disorders consist of two pre-clinical programs, OTL-104 for Crohn’s disease with mutations in the nucleotide-binding oligomerization domain-containing protein 2 (NOD2-CD), and OTL-105 for hereditary angioedema (HAE).
What is the current price of ORTX stock?
The current stock price of ORTX is 16.7 USD. The price increased by 0.3% in the last trading session.
What is the dividend status of ORCHARD THERAPEUTICS PLC-ADR?
ORTX does not pay a dividend.
What is the ChartMill rating of ORCHARD THERAPEUTICS PLC-ADR stock?
ORTX has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What do analysts say about ORCHARD THERAPEUTICS PLC-ADR (ORTX) stock?
7 analysts have analysed ORTX and the average price target is 16.32 USD. This implies a price decrease of -2.28% is expected in the next year compared to the current price of 16.7.
Can you provide the sector and industry classification for ORCHARD THERAPEUTICS PLC-ADR?
ORCHARD THERAPEUTICS PLC-ADR (ORTX) operates in the Health Care sector and the Biotechnology industry.